Comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

Vertebroplasty may provoke fractures in adjacent, nonaugmented vertebrae.

Subsequent VCFs can occur much sooner and more frequently after PVPs.

Who Took Part

According to the abstract, 32 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

Comparing a prospective group of 32 patients, who underwent percutaneous vertebroplasty (PVP) and who were treated with teriparatide for at least 18 months after a new-onset adjacent vertebral compression fracture (VCF), and compared it with a retrospective group of 33 patients, who received antiresorptive agents combined with repeated PVPs for post-PVP new-onset adjacent VCFs.

Relevant clinical data were compared between a prospective group of patients who received teriparatide and a retrospective group of patients who received antiresorptive agents and repeated PVPs for new-onset adjacent VCFs after PVP.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Teriparatide and who got the comparison, which limits bias.

What Was Measured

The subject headings attached to it are Bone Density Conservation Agents, Combined Modality Therapy, Fractures, Compression, Osteoporotic Fractures, Spinal Fractures, Teriparatide and Vertebroplasty.

What This Means in Plain Language

The paper is a randomized study of Teriparatide in 32 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (Journal of spinal disorders & techniques), a journal based in United States.

More context: the Teriparatide compound page, all human trials.